

Gioacchino Angarano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8716418/publications.pdf>

Version: 2024-02-01

112
papers

3,624
citations

147801
31
h-index

144013
57
g-index

112
all docs

112
docs citations

112
times ranked

4365
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. <i>Aids</i> , 2000, 14, 499-507.	2.2	483
2	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	4.0	385
3	Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. <i>Aids</i> , 2000, 14, F123-F128.	2.2	195
4	Gender Differences in Antiretroviral Drug-Related Adipose Tissue Alterations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 58-61.	2.1	111
5	Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug-Naïve Patients Treated with Protease Inhibitor-Based Therapy. <i>Journal of Infectious Diseases</i> , 2001, 184, 983-991.	4.0	104
6	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. <i>PLoS ONE</i> , 2010, 5, e13540.	2.5	94
7	Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. <i>Aids</i> , 2003, 17, 2169-2176.	2.2	93
8	The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 352-360.	2.1	90
9	The Biological Phenotype of HIV-1 Is Usually Retained during and after Sexual Transmission. <i>Virology</i> , 1994, 204, 297-303.	2.4	78
10	RAPID SPREAD OF HTLV-III INFECTION AMONG DRUG ADDICTS IN ITALY. <i>Lancet</i> , The, 1985, 326, 1302.	13.7	70
11	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 1164-1173.	5.8	70
12	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 1018-1024.	4.0	66
13	Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 32, 268-280.	2.1	60
14	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179.	2.3	60
15	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
16	Detection of Human Herpesvirus 8 in Cervicovaginal Secretions and Seroprevalence in Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Women. <i>Journal of Infectious Diseases</i> , 1999, 179, 1534-1537.	4.0	56
17	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015, 12, 33.	2.0	55
18	Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. <i>Aids</i> , 1998, 12, 737-743.	2.2	53

#	ARTICLE	IF	CITATIONS
19	Gaining Back What Is Lost: Recovering the Sense of Smell in Mild to Moderate Patients After COVID-19. <i>Chemical Senses</i> , 2020, 45, 875-881.	2.0	52
20	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. <i>PLoS ONE</i> , 2014, 9, e94768.	2.5	50
21	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014, 11, 49.	2.0	48
22	HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. <i>Journal of Medical Virology</i> , 2005, 75, 483-490.	5.0	46
23	COVID-19 infection in Crohn's disease under treatment with adalimumab. <i>Gut</i> , 2020, 69, 1364-1365.	12.1	46
24	Gastrointestinal infection due to <i>Anisakis simplex</i> in southern Italy. <i>European Journal of Epidemiology</i> , 2000, 16, 75-78.	5.7	45
25	Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1150-1154.	3.0	42
26	Prevalence of <i>Plasmodium</i> spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. <i>Malaria Journal</i> , 2009, 8, 12.	2.3	41
27	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 263-271.	2.1	39
28	Biological correlates of HIV-1 heterosexual transmission. <i>Aids</i> , 1997, 11, 1089-1094.	2.2	38
29	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. <i>Hepatology</i> , 2014, 59, 2101-2109.	7.3	38
30	Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. <i>Journal of the Neurological Sciences</i> , 2020, 416, 117011.	0.6	36
31	Coreceptor switch during HAART is independent of virological success. <i>Journal of Medical Virology</i> , 2009, 81, 2036-2044.	5.0	35
32	Impact of Mutations Outside the V3 Region on Coreceptor Tropism Phenotypically Assessed in Patients Infected with HIV-1 Subtype B. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5078-5084.	3.2	32
33	Intracellular and cell-free (infectious) HIV-1 in rectal mucosa. <i>Journal of Medical Virology</i> , 2001, 65, 637-643.	5.0	29
34	HBV DNA suppression and HBsAg clearance in HBsAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258.	3.7	29
35	Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men. <i>Infection, Genetics and Evolution</i> , 2014, 23, 176-181.	2.3	29
36	Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1178-1184.	1.1	28

#	ARTICLE	IF	CITATIONS
37	Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 623-630.	1.2	27
38	Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 896-900.	3.0	27
39	HIV-1 variability and progression to AIDS: A longitudinal study. <i>Journal of Medical Virology</i> , 1990, 32, 252-256.	5.0	26
40	Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort. <i>Atherosclerosis</i> , 2017, 263, 398-404.	0.8	25
41	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
42	Early Markers of Tubular Dysfunction in Antiretroviral-Experienced HIV-Infected Patients Treated with Tenofovir Versus Abacavir. <i>AIDS Patient Care and STDs</i> , 2012, 26, 5-11.	2.5	24
43	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	4.1	24
44	Disseminated <i>Mycobacterium terrae</i> Infection in a Patient with Advanced Human Immunodeficiency Virus Disease. <i>Clinical Infectious Diseases</i> , 2000, 30, 831-835.	5.8	23
45	Opportunistic Parasitic Infections of the Intestinal Tract in the Era of Highly Active Antiretroviral Therapy: Is the CD4+Count So Important?. <i>Clinical Infectious Diseases</i> , 2001, 33, 1609-1611.	5.8	23
46	Giardiasis in HIV: a possible role in patients with severe immune deficiency. <i>European Journal of Epidemiology</i> , 1997, 13, 485-487.	5.7	21
47	Community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 261-273.	2.6	20
48	Familial clustering of HBV pre-C and pre-S mutants. <i>Journal of Hepatology</i> , 1997, 26, 221-227.	3.7	19
49	HIV-1 Phenotypic Susceptibility to Lopinavir (LPV) and Genotypic Analysis in LPV/r-Naive Subjects With Prior Protease Inhibitor Experience. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 439-447.	2.1	19
50	An outbreak of HIV-1 BC recombinants in Southern Italy. <i>Journal of Clinical Virology</i> , 2012, 55, 370-373.	3.1	19
51	Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. <i>Clinical Drug Investigation</i> , 2021, 41, 437-448.	2.2	19
52	Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 37, 1587-1598.	2.1	18
53	Intrafamilial Transmission of Human Herpesvirus 8. <i>Journal of the National Cancer Institute</i> , 2001, 93, 154-156.	6.3	17
54	Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART. <i>Journal of Medical Virology</i> , 2003, 70, 1-9.	5.0	16

#	ARTICLE	IF	CITATIONS
55	Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. <i>Journal of Medical Virology</i> , 2008, 80, 1695-1706.	5.0	16
56	X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the inflamm-aging process. <i>BMC Infectious Diseases</i> , 2013, 13, 220.	2.9	15
57	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	1.9	15
58	Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 817-842.	2.4	15
59	High seroprevalence of human herpesvirus 8 (HHV-8) in HIV-1-infected pregnant women of Southeastern Italy: Association with injection drug use and hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2004, 72, 656-660.	5.0	14
60	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 339-345.	2.1	14
61	<i>Sphingomonas paucimobilis</i> outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection. <i>American Journal of Infection Control</i> , 2020, 48, 1267-1269.	2.3	14
62	Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. <i>In Vivo</i> , 2017, 31, 125-132.	1.3	13
63	Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission. <i>Aids</i> , 1993, 7, 29-32.	2.2	10
64	Highly Active Antiretroviral Therapy Failure and Protease and Reverse Transcriptase Human Immunodeficiency Virus Type 1 Gene Mutations. <i>Journal of Infectious Diseases</i> , 1999, 180, 568-571.	4.0	10
65	Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naïve HIV-1-positive individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1580-1587.	3.0	10
66	Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab187.	0.9	10
67	Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode?. <i>Aids</i> , 2002, 16, 947-948.	2.2	10
68	Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. <i>BMC Infectious Diseases</i> , 2020, 20, 196.	2.9	9
69	Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women largely treated with antiretroviral agents. <i>Aids</i> , 1999, 13, 992.	2.2	8
70	Are the Proposed env Mutations Actually Associated With Resistance to Maraviroc?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 550-552.	2.1	8
71	Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir±sofosbuvir in HCV-infected patients with or without HIV infection: a multicentre observational study. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 296-301.	2.5	8
72	The elderly and direct antiviral agents: Constraint or challenge?. <i>Digestive and Liver Disease</i> , 2017, 49, 1036-1042.	0.9	8

#	ARTICLE	IF	CITATIONS
73	HIV-1 disease progression in women: role of the viral phenotype of the HIV-positive steady partner. <i>Aids</i> , 1999, 13, 1801.	2.2	8
74	HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. <i>Journal of Medical Virology</i> , 2005, 77, 457-459.	5.0	7
75	Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsychotic drugs. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 191-194.	2.4	7
76	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 29-33.	5.0	6
77	Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects. <i>Antiviral Research</i> , 2009, 83, 118-126.	4.1	6
78	A Greater Prevalence of X4 Viruses in HIV Type 1 Intravenous Drug Users Reflects a Δ CD4 ⁺ Effect. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1029-1031.	1.1	6
79	Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009. <i>Journal of Chemotherapy</i> , 2012, 24, 113-121.	1.5	6
80	Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. <i>Digestive and Liver Disease</i> , 2017, 49, 530-534.	0.9	6
81	Local Epidemics Gone Viral: Evolution and Diffusion of the Italian HIV-1 Recombinant Form CRF60_BC. <i>Frontiers in Microbiology</i> , 2019, 10, 769.	3.5	6
82	Drug Injection in Jugular Veins: A New Risk Factor for Vascular Diseases in HIV-Infected Patients?. <i>Angiology</i> , 1995, 46, 1049-1052.	1.8	5
83	Immunological markers in HIV-infected pregnant and non-pregnant women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 90, 37-41.	1.1	5
84	Both a Protective and a Deleterious Role for the L76V Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1724-1725.	3.2	5
85	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19825.	3.0	5
86	Opera: Use of Pegylated Interferon plus Ribavirin for Treating HCV/HIV Coinfection in Interferon-Naïve Patients. <i>Antiviral Therapy</i> , 2014, 19, 735-745.	1.0	5
87	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2001, 6, 195-198.	1.0	5
88	HIV-1 Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic/Phenotypic Correlations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 1104-1107.	2.1	4
89	Prolonged Lamivudine Treatment in Patients with Chronic Active Anti-HBe ⁺ Positive Hepatitis. <i>American Journal of Therapeutics</i> , 2006, 13, 218-222.	0.9	4
90	Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2009, 3, 9132.	0.8	4

#	ARTICLE	IF	CITATIONS
91	Emerging issue of fluconazole-resistant candidemia in a tertiary care hospital of southern Italy: time for antifungal stewardship program. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101206.	1.5	4
92	The Role of HIV Type 1 Phenotype and Genotype in Long-Term Responders to Zidovudine Therapy. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 969-975.	1.1	3
93	Difficulties in Classifying A/G Recombinants: Methodological Problems or Genetic Variability?. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 840-846.	1.1	3
94	V3 Sequences and Paired HIV Isolates from 52 Non-Subtype B HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 365-372.	1.1	3
95	Improved Virological Outcome in Non-B Patients: A Possible Role for Baseline Coreceptor Tropism. <i>Clinical Infectious Diseases</i> , 2012, 55, 165-167.	5.8	3
96	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	2.5	3
97	Limiting Severe Outcomes and Impact on Intensive Care Units of Moderate-Intermediate 2009 Pandemic Influenza: Role of Infectious Diseases Units. <i>PLoS ONE</i> , 2012, 7, e42940.	2.5	3
98	Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. <i>New Microbiologica</i> , 2018, 41, 112-117.	0.1	3
99	Efficacy of protease inhibitor-based anti-retroviral therapy in severe HIV-associated thrombocytopenia unresponsive to AZT. <i>British Journal of Haematology</i> , 1999, 105, 1147-1149.	2.5	2
100	A Multidrug-Resistant (MDR) HIV Type 1 Infection in a Homosexual Man and Identified Source Patient. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1293-1295.	1.1	2
101	Prevalence of Urinary Schistosomiasis in Migrants in Apulia, a Region of Southern Italy, in the Years 2006-2016. <i>BioMed Research International</i> , 2017, 2017, 1-6.	1.9	2
102	Influence of HLA-B*57:01 on liver fibrosis progression in a cohort of HIV/HCV coinfecting individuals. <i>Journal of Medical Virology</i> , 2019, 91, 751-757.	5.0	2
103	Lost to follow-up: a challenge over 10 years. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1621-1626.	1.2	2
104	Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection. <i>In Vivo</i> , 2015, 29, 771-5.	1.3	2
105	HIV-1 nonsubtype B distribution across certain resource-rich countries. <i>HIV Therapy</i> , 2009, 3, 467-483.	0.6	1
106	Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients. <i>Current HIV Research</i> , 2009, 7, 425-433.	0.5	1
107	Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates. <i>Virology</i> , 2019, 535, 266-271.	2.4	1
108	Circulating immune complexes in HBsAg-positive and HBsAg-negative chronic liver diseases. <i>Research in Clinic and Laboratory</i> , 1984, 14, 29-35.	0.3	1

#	ARTICLE	IF	CITATIONS
109	NON-A, NON-B HEPATITIS VIRUS. Lancet, The, 1985, 325, 169-171.	13.7	0
110	Epidemiological Multicentric Italian Society of Infectious and Tropical Diseases Study on Prevalence of Tropical Diseases in Hospitalized Immigrants in Italy During 2002. Infectious Diseases in Clinical Practice, 2008, 16, 105-108.	0.3	0
111	HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio. PLoS ONE, 2019, 14, e0212882.	2.5	0
112	Influence of HIV-1 V2 sequence variability on bacterial translocation in antiretroviral naïve HIV-1 infected patients. Journal of Medical Virology, 2020, 92, 3271-3278.	5.0	0